for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

I'rom Group Co Ltd

2372.T

Latest Trade

1,642.00JPY

Change

15.00(+0.92%)

Volume

36,600

Today's Range

1,626.00

 - 

1,651.00

52 Week Range

1,370.00

 - 

2,479.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,627.00
Open
1,627.00
Volume
36,600
3M AVG Volume
1.84
Today's High
1,651.00
Today's Low
1,626.00
52 Week High
2,479.00
52 Week Low
1,370.00
Shares Out (MIL)
11.51
Market Cap (MIL)
18,857.44
Forward P/E
16.76
Dividend (Yield %)
1.25

Next Event

Dividend For 2372.T - 20.0000 JPY

Latest Developments

More

I'rom Group Co Ltd Says To Buy Back Up To 1.12 Percent Of Own Shares Worth 200 Million Yen Through March 29

I'rom Group unit signs license agreement with Censo Biotechnologies

I'rom Group unit concludes iPS cell generation technology licensing agreement with UK-based Elpis Biomed

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About I'rom Group Co Ltd

I'rom Group Co.,Ltd., formerly I'rom Holdings Co. Ltd., is a Japan-based company. The Site Management Organization (SMO) segment provides support services for clinical trial facilities. The Medical Supports segment establishes and leases clinic complex facilities, as well as provides medical consulting and support services. The Others segment is engaged in the other businesses.

Industry

Biotechnology & Drugs

Contact Info

Iidabashi Grand Bloom, 2-10-2, Fujimi

+81.3.32643148

http://www.iromgroup.co.jp/

Executive Leadership

Toyotaka Mori

President, President of Subsidiary, Representative Director

Tsugumine Shu

Vice President, Director

Shuichi Kojima

Managing Executive Officer, Director of Business Planning

Toshiya Hara

Executive Director

Hiroaki Inukai

Executive Director

Key Stats

Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

18.770

2018

135.350

2019

78.310

2020(E)

95.800
Price To Earnings (TTM)
21.24
Price To Sales (TTM)
1.78
Price To Book (MRQ)
3.04
Price To Cash Flow (TTM)
16.93
Total Debt To Equity (MRQ)
86.08
LT Debt To Equity (MRQ)
55.28
Return on Investment (TTM)
9.93
Return on Equity (TTM)
7.26

Latest News

BRIEF- I'rom Group unit ID Pharma signs iPS cell generation technology licensing agreement with U.S.-based QurAlis

* Says its wholly owned unit ID Pharma concluded an iPS cell generation technology licensing agreement with U.S.-based QurAlis Corporation

BRIEF-I'rom Group unit signs iPS cell tech related license agreement with Q-State Biosciences

* Says co's wholly owned unit ID Pharma signs iPS cell (induced pluripotent stem cell) technology related license agreement with U.S.-based firm Q-State Biosciences Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up